Pelvic exenteration for vulvovaginal carcinoma

Area of Science:

• Gynecologic Oncology
• Surgical Oncology
• Oncology

Background:

• Vulvovaginal carcinoma, particularly advanced or recurrent cases, presents significant treatment challenges.
• Pelvic exenteration is a radical surgical option for locally advanced or recurrent pelvic malignancies.
• Historical data on the outcomes of pelvic exenteration for vulvovaginal carcinoma are crucial for treatment planning.

Purpose of the Study:

• To evaluate the outcomes of pelvic exenteration in patients with advanced and recurrent vulvovaginal carcinoma.
• To determine the survival rates and complications associated with this extensive surgical procedure.
• To assess the efficacy of pelvic exenteration in managing complex vulvovaginal cancers.

Main Methods:

• Retrospective review of 16 patients who underwent pelvic exenteration between 1964 and 1978.
• Analysis of patient demographics, cancer stage, extent of disease involvement (anus/sphincter, urethra, vagina), and surgical procedures.
• Assessment of postoperative outcomes, including survival rates, disease recurrence, and causes of mortality.

Main Results:

• The study included 16 patients with advanced or recurrent vulvovaginal carcinoma, with various stages and sites of involvement.
• Seven patients achieved disease-free survival, with six surviving over 5 years.
• The absolute 5-year survival rate was 54%, with perioperative mortality and late disease-free deaths reported.

Conclusions:

• Pelvic exenteration can achieve long-term disease-free survival in a significant proportion of patients with advanced or recurrent vulvovaginal carcinoma.
• The procedure is associated with considerable morbidity and mortality, necessitating careful patient selection and surgical expertise.
• This study highlights the role of pelvic exenteration as a potentially curative option for complex vulvovaginal cancers, despite the associated risks.